首頁 > 市場調查報告書 > 醫療設備

醫學影像診斷體外診斷癌症癌症診斷

市場調查報告書

商品編碼

2126327

乳癌診斷市場：策略性洞察與預測（2026-2035）

Breast Cancer Diagnostics Market - Strategic Insights and Forecasts (2026-2035)

出版日期: 2026年08月03日 | 出版商:

Knowledge Sourcing Intelligence | 英文 170 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計乳癌診斷市場規模將從 2026 年的 160 億美元成長到 2035 年的 259 億美元，複合年成長率為 5.5%。

乳癌診斷市場正經歷一場重大變革，其驅動力在於模式轉移。這一市場演變的特點是，人們日益認知到治療決策越來越依賴全面的分子特徵分析，而不僅僅是組織學評估。先進影像系統、數位病理學、次世代定序和人工智慧的融合，使得病灶檢測、病理確認和預測性生物標記的辨識更加精準。隨著早期發現顯著改善臨床療效和治療選擇，系統性篩檢計畫在醫療保健系統中不斷擴展。隨著精準腫瘤學的日益普及，對能夠識別HER2表達、激素受體狀態、BRCA突變、PIK3CA突變和其他臨床相關基因組標記物的檢驗生物標記檢測的需求也日益成長。診斷設備製造商正透過自動化、數位化整合和伴隨診斷的開發來擴展產品系列，以支援個人化治療路徑。隨著人工智慧影像解決方案、液態生物檢體技術和多分子檢測技術的大量投資進入市場，乳癌診斷正在成為全球醫療保健系統中個人化癌症治療的重要基礎。

市場促進因素

精準腫瘤學的日益普及是乳癌診斷市場的主要驅動力。精準腫瘤學高度依賴分子特徵分析，以匹配合適的標靶治療，因此生物標記檢測是乳癌管理的關鍵環節。基因組分析在臨床實踐中的應用日益廣泛，因為治療合格取決於對預測性生物標記（例如HER2、激素受體、BRCA1/2和PIK3CA突變）的準確識別。這種依賴性推動了對高靈敏度分子檢測的需求，這些檢測能夠在不同的臨床環境中提供可重複的結果。診斷設備製造商正透過與開發標靶治療的製藥公司合作，擴展其伴隨診斷產品組合，從而持續提高基於生物標記的診斷方法的使用率。系統性篩檢計畫透過增加診斷數量，進一步加速了市場成長。基於人群的乳癌篩檢仍然是症狀出現前識別疾病的基本機制。由於早期發現能夠顯著改善臨床結果和治療選擇，全球醫療保健系統正在不斷擴大篩檢參與。可疑病灶的日益增多導致對影像檢查、切片檢查、病理評估和分子檢測等確診手段的需求持續成長。因此，醫療機構正投資於先進的乳房X光攝影系統、乳房斷層合成成像、乳房磁振造影、超音波以及人工智慧成像技術，以應對不斷成長的患者群體，同時保持診斷的準確性。人工智慧的整合正在提高診斷效率並最佳化工作流程。影像檢查工作量的增加給放射科帶來了營運壓力，他們必須在保證診斷品質的同時解決人員短缺問題。人工智慧影像分析透過優先處理可疑觀察、提高病灶檢出率和最佳化工作流程，正日益為放射科醫師提供支援。這種技術的整合減少了解讀結果的差異，同時使臨床醫生能夠專注於複雜的診斷病例。醫學影像公司正在不斷開發可與現有影像歸檔和通訊系統（PACS）整合的軟體，從而促進其在醫療機構中的更廣泛應用。分子檢測的擴展透過全面的疾病特徵分析，支持個體化的臨床決策。乳癌包含多種生物學上不同的疾病亞型，每種亞型都需要不同的治療策略。全面的分子譜分析能夠實現超越傳統病理檢測的風險分層和預後評估，促使診斷檢查室擴大採用基因組檢測。標靶治療的日益普及進一步凸顯了準確檢測生物標記的臨床重要性，促使醫療機構在整個患者照護過程中規範分子檢測流程。

市場限制因素

先進影像系統、分子診斷平台和數位病理基礎設施的高昂實施和維修成本持續限制資源匱乏的醫療機構的採用。先進技術所需的大量資本投入對小規模的醫療機構和診所而言是一大障礙。基因組檢測和先進分子診斷的報銷政策差異，降低了部分地區的檢測可近性，並影響了醫療採購決策。保險覆蓋範圍的不一致限制了患者獲得先進檢測服務的機會。分析檢驗、臨床證據產生、軟體檢驗和上市後監測等方面的監管要求，增加了診斷設備製造商的產品開發時間和商業化成本。嚴格的核准流程對小規模的診斷設備製造商構成挑戰。病理學和分子診斷專業知識的匱乏，限制了先進診斷平台的有效利用，並限制了擴充性應用。

依產品
- 裝置
- 試劑和耗材
- 軟體和服務
透過技術
- 乳房X光檢查
- 乳腺超音波檢查
- 磁振造影（MRI）
- 電腦斷層掃描（CT）
- 切片檢查
- 其他診斷技術
透過生物標記
- 荷爾蒙受體
  - 雌激素受體（ER）
  - 黃體素受體（PR）
- 遺傳標記
- 其他生物標記
依樣本類型
- 組織
- 血
- 細針穿刺檢體
- 其他檢體類型
透過使用
- 篩檢和早期檢測
- 診斷和風險管理
- 預後
- 伴隨診斷
- 疾病和治療監測
- 其他
最終用戶
- 醫院
- 診斷檢查室
- 癌症中心
- 其他

第10章：全球乳癌診斷市場：區域分析

北美洲
歐洲
亞太地區
南美洲
中東和非洲

第11章全球乳癌診斷市場：國別分析

美國
加拿大
德國
英國
法國
義大利
西班牙
日本
中國
印度
韓國
澳洲
巴西
墨西哥
沙烏地阿拉伯

第12章競爭格局

市佔率分析
策略趨勢
併購、合作與聯盟
新產品發布

第13章：公司簡介

Hologic, Inc.
Roche Holding AG
Siemens AG
GE HealthCare Technologies Inc.
Koninklijke Philips NV
Fujifilm Holdings Corporation
NeoGenomics, Inc.
Illumina, Inc.
QIAGEN NV
Becton, Dickinson and Company

第14章全球乳癌診斷市場：商業預測分析

第15章投資與資金籌措分析

創業投資趨勢
政府資金
研發投資

第16章：未來展望

主要成長機遇
未來產業趨勢

簡介目錄

Product Code: KSI-009040

The Breast Cancer Diagnostics Market is expected to grow at a CAGR of 5.5% from a market value of USD 16.0 billion in 2026 to USD 25.9 billion in 2035.

The breast cancer diagnostics market is undergoing significant transformation driven by the paradigm shift toward integrated diagnostic pathways and precision oncology. The market's evolution is characterized by the growing recognition that treatment decisions increasingly depend on comprehensive molecular characterization rather than histological evaluation alone. The convergence of advanced imaging systems, digital pathology, next-generation sequencing, and artificial intelligence is enabling more accurate lesion detection, pathological confirmation, and predictive biomarker identification. Healthcare systems are expanding organized screening programs because early-stage detection substantially improves clinical outcomes and treatment options. The rising adoption of precision oncology is increasing demand for validated biomarker assays capable of identifying HER2 expression, hormone receptor status, BRCA mutations, PIK3CA alterations, and other clinically relevant genomic markers. Diagnostic manufacturers are expanding product portfolios through automation, digital integration, and companion diagnostic development to support individualized treatment pathways. The market is witnessing significant investment in AI-enabled imaging solutions, liquid biopsy technologies, and multiplex molecular assays, positioning breast cancer diagnostics as an essential foundation of personalized cancer care across global healthcare systems.

Market Drivers

The increasing adoption of precision oncology represents the primary driver for the breast cancer diagnostics market. Precision oncology increasingly relies on molecular characterization to match patients with targeted therapies, making biomarker testing an essential component of breast cancer management. Clinical practice is increasingly incorporating genomic profiling because therapeutic eligibility depends on accurate identification of predictive biomarkers such as HER2, hormone receptors, BRCA1/2, and PIK3CA alterations. This dependency raises demand for highly sensitive molecular assays that deliver reproducible results across diverse clinical settings. Diagnostic manufacturers are expanding companion diagnostic portfolios through collaborations with pharmaceutical companies developing targeted therapies, resulting in sustained growth in biomarker-based diagnostic utilization. Organized screening programs are further accelerating market growth by increasing diagnostic volumes. Population-based breast cancer screening remains a fundamental mechanism for identifying disease before symptom onset. National healthcare systems are continuing to expand screening participation because early-stage detection substantially improves clinical outcomes and treatment options. Increased identification of suspicious lesions creates sustained demand for diagnostic imaging, biopsy procedures, pathology assessment, and confirmatory molecular testing. Healthcare providers are therefore investing in advanced mammography systems, breast tomosynthesis, breast MRI, ultrasound, and AI-assisted image interpretation to manage growing patient volumes while maintaining diagnostic accuracy. Artificial intelligence integration is improving diagnostic efficiency and workflow optimization. Growing imaging workloads create operational pressure for radiology departments that must maintain diagnostic quality while addressing workforce limitations. AI-enabled image analysis is increasingly assisting radiologists by prioritizing suspicious findings, improving lesion detection, and supporting workflow optimization. This technological integration reduces interpretation variability while enabling clinicians to focus on complex diagnostic cases. Medical imaging companies are continuously developing software capable of integrating with existing picture archiving and communication systems, encouraging broader institutional adoption. Expanding molecular testing is supporting personalized clinical decision-making through comprehensive disease characterization. Breast cancer encompasses biologically diverse disease subtypes that require different therapeutic strategies. Diagnostic laboratories are increasingly incorporating genomic assays because comprehensive molecular profiling improves risk stratification and prognosis assessment beyond conventional pathology. Growing availability of targeted therapies reinforces the clinical importance of accurate biomarker detection, encouraging healthcare providers to standardize molecular testing across patient care pathways.

Market Restraints

High acquisition and maintenance costs associated with advanced imaging systems, molecular diagnostic platforms, and digital pathology infrastructure continue to limit adoption among resource-constrained healthcare providers. The substantial capital investment required for advanced technologies creates barriers for smaller facilities and practices. Variability in reimbursement policies for genomic testing and advanced molecular diagnostics reduces testing accessibility and influences healthcare provider purchasing decisions across several regions. Inconsistent coverage policies limit patient access to advanced testing options. Regulatory requirements for analytical validation, clinical evidence generation, software verification, and post-market surveillance increase product development timelines and commercialization costs for diagnostic manufacturers. The rigorous approval processes create challenges for smaller diagnostic companies. Shortages of specialized pathology and molecular diagnostics expertise constrain efficient utilization of advanced diagnostic platforms, limiting scalability in many healthcare settings.

Technology and Segment Insights

The technology landscape is characterized by the growing importance of integrated diagnostic workflows. Demand continues to shift toward integrated diagnostic pathways because treatment decisions increasingly depend on comprehensive molecular characterization rather than histological evaluation alone. This transition is expanding the role of NGS, digital pathology, AI-assisted image interpretation, multiplex immunohistochemistry, and companion diagnostics across oncology practices. Hospitals and cancer centers are consequently adopting multimodal diagnostic workflows that combine radiological, pathological, and genomic information. Mammography remains the primary screening modality, with digital breast tomosynthesis gaining adoption for improved lesion detection. Breast ultrasound and MRI serve as complementary imaging tools for diagnostic confirmation and high-risk screening. Biopsy procedures provide tissue for pathological and molecular evaluation. The segment analysis reveals that reagents and consumables represent the recurring component of the market because every diagnostic workflow depends on assay-specific kits, antibodies, probes, staining reagents, sequencing reagents, and quality control materials. Demand is increasing as healthcare providers perform larger numbers of screening, IHC, FISH, PCR, and NGS tests across both centralized and decentralized laboratory settings. Screening and early detection constitute a fundamental application segment because clinical outcomes improve substantially when breast cancer is identified before disease progression. Organized screening programs are increasing the number of women undergoing mammography and supplemental imaging, creating sustained demand for confirmatory diagnostic procedures. Hormone receptor testing and HER2 testing remain essential for therapeutic selection, with genetic marker testing expanding for hereditary risk assessment and treatment guidance. Hospitals remain the primary end users because they provide integrated diagnostic, surgical, pathological, and oncological services within a coordinated clinical environment. Diagnostic laboratories and cancer centers are expanding specialized testing services to support precision oncology programs. The integration of AI is becoming increasingly important across imaging and pathology workflows, with AI-enabled solutions assisting radiologists and pathologists in lesion detection, biomarker quantification, and workflow prioritization.

Competitive and Strategic Outlook

The competitive landscape features established imaging and diagnostic companies alongside specialized molecular testing and precision oncology providers. Hologic differentiates itself through its exclusive focus on women's health, supported by a comprehensive portfolio of breast imaging, biopsy, and diagnostic technologies, continuing to expand AI-enabled mammography and breast health solutions. Roche maintains a leading position in precision oncology by combining molecular diagnostics, tissue diagnostics, and companion diagnostic development with its pharmaceutical portfolio, continuing to invest in biomarker-driven diagnostics that support personalized breast cancer treatment. Siemens Healthineers leverages advanced imaging, AI, and digital healthcare platforms to strengthen breast cancer diagnostics, continuing to enhance workflow automation and image quality. GE HealthCare focuses on intelligent imaging solutions that integrate AI, digital workflow optimization, and advanced visualization technologies, with breast imaging innovations supporting earlier lesion detection. Philips differentiates itself through connected care and integrated diagnostic ecosystems that combine imaging technologies with digital informatics. Fujifilm combines digital imaging expertise with advanced mammography technologies to support breast cancer screening and diagnosis. NeoGenomics specializes in oncology-focused laboratory services and comprehensive molecular testing for precision medicine. Illumina remains a global leader in NGS technologies that enable comprehensive genomic profiling in oncology. Companies are pursuing product portfolio expansion through innovation in AI-enabled imaging, digital pathology, liquid biopsy, and companion diagnostic technologies. Strategic collaborations between diagnostic manufacturers and pharmaceutical companies are increasing, driven by the need for companion diagnostic development alongside targeted therapies. Recent key developments include Perimeter Medical Imaging AI's Claire OCT System receiving FDA premarket approval as the first AI-enabled imaging device approved in the US for intraoperative assessment of breast cancer margins. DeepHealth launched Breast Suite, bringing together AI-powered breast cancer detection, breast density assessment, and risk assessment technologies. Hologic presented new data on its AI-powered mammography technology at the Society of Breast Imaging Annual Symposium. GE HealthCare launched Invenia ABUS Premium, an AI-driven 3D breast ultrasound for early cancer detection in dense breasts. Geographic expansion remains a key strategic priority, with companies targeting rapidly growing Asia Pacific and emerging markets where healthcare infrastructure is expanding.

Short Conclusion

The breast cancer diagnostics market is positioned for sustained growth driven by the convergence of organized screening programs, precision oncology adoption, and technological innovation. The transition from standalone detection technologies toward integrated precision oncology platforms represents a fundamental shift in breast cancer management. While challenges related to high costs, reimbursement variability, and regulatory complexity persist, strategic investments in technology, automation, and partnerships are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with breast cancer diagnostics evolving into an essential foundation of personalized cancer care, supporting early detection, accurate diagnosis, therapeutic selection, and longitudinal disease monitoring across global healthcare systems.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation, and trade analysis
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

1. Executive Summary

1.1 Market Snapshot
1.2 Key Findings
1.3 Analyst Insights
1.4 Strategic Recommendations

2. Research Methodology

2.1 Research Design
2.2 Data Collection Methodology
2.3 Market Size Estimation
2.4 Forecasting Model
2.5 Assumptions & Limitations

3. Global Breast Cancer Diagnostics Market Overview, Size & Forecast

3.1 Market Definition & Scope
3.2 Breast Cancer Overview
3.3 Disease Classification
3.4 Disease Burden & Unmet Clinical Needs
3.5 Epidemiology Analysis
- 3.5.1 Disease Prevalence
- 3.5.2 Incidence Analysis
- 3.5.3 Diagnosed Patient Population
- 3.5.4 Screening-Eligible Population
3.6 Patient Journey Analysis
3.7 Breast Cancer Diagnostic Pathway
3.8 Industry Evolution
3.9 Key Market Trends
3.10 Historical Market Size Analysis (2021-2025)
3.11 Market Forecast (2026-2035)

4. Market Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Market Challenges

5. Industry Landscape

5.1 Industry Value Chain Analysis
5.2 Pricing Analysis
5.3 Reimbursement Landscape

6. Innovation Landscape

6.1 Emerging Technologies
6.2 Product Innovation
6.3 Clinical Trial Analysis
6.4 Pipeline Analysis
6.5 Artificial Intelligence Integration in Breast Cancer Diagnostics
6.6 Digital Health Integration
6.7 Technology Roadmap

7. Regulatory Landscape

7.1 Regulatory Framework
7.2 Approval Pathways
7.3 Compliance Requirements

8. Global Breast Cancer Diagnostics Market Landscape Analysis

8.1 Analysis by Technology Platform
8.2 Analysis by Biomarker
8.3 Analysis by Sample Type
8.4 Analysis by Clinical Application
8.5 Analysis by Testing Methodology

9. Global Breast Cancer Diagnostics Market Segment Analysis (2021-2035)

9.1 By Product
- 9.1.1 Instruments
- 9.1.2 Reagents & Consumables
- 9.1.3 Software & Services
9.2 By Technology
- 9.2.1 Mammography
- 9.2.2 Breast Ultrasound
- 9.2.3 Magnetic Resonance Imaging (MRI)
- 9.2.4 Computed Tomography (CT)
- 9.2.5 Biopsy
- 9.2.6 Other Diagnostic Technologies
9.3 By Biomarker
- 9.3.1 Hormone Receptors
  - 9.3.1.1 Estrogen Receptor (ER)
  - 9.3.1.2 Progesterone Receptor (PR)
- 9.3.3 Genetic Markers
- 9.3.4 Other Biomarkers
9.4 By Sample Type
- 9.4.1 Tissue
- 9.4.2 Blood
- 9.4.3 Fine Needle Aspiration Samples
- 9.4.4 Other Sample Types
9.5 By Application
- 9.5.1 Screening & Early Detection
- 9.5.2 Diagnosis & Risk Management
- 9.5.3 Prognosis
- 9.5.4 Companion Diagnostics
- 9.5.5 Disease and Treatment Monitoring
- 9.5.6 Others
9.6 By End User
- 9.6.1 Hospitals
- 9.6.2 Diagnostic Laboratories
- 9.6.3 Cancer Centers
- 9.6.4 Others

10. Global Breast Cancer Diagnostics Market Geographical Analysis (2021-2035)

10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 South America
10.5 Middle East & Africa

11. Global Breast Cancer Diagnostics Market Country Analysis (2021-2035)

11.1 United States
11.2 Canada
11.3 Germany
11.4 United Kingdom
11.5 France
11.6 Italy
11.7 Spain
11.8 Japan
11.9 China
11.10 India
11.11 South Korea
11.12 Australia
11.13 Brazil
11.14 Mexico
11.15 Saudi Arabia

12. Competitive Landscape

12.1 Market Share Analysis
12.2 Strategic Developments
12.3 Mergers & Acquisitions, Partnerships & Collaborations
12.4 Product Launches

13. Company Profiles

13.1 Hologic, Inc.
- 13.1.1 Company Overview
- 13.1.2 Financials
- 13.1.3 Product Portfolio
- 13.1.4 Recent Developments
13.2 Roche Holding AG
13.3 Siemens AG
13.4 GE HealthCare Technologies Inc.
13.5 Koninklijke Philips N.V.
13.6 Fujifilm Holdings Corporation
13.7 NeoGenomics, Inc.
13.8 Illumina, Inc.
13.9 QIAGEN N.V.
13.10 Becton, Dickinson and Company